Hikma Pharmaceuticals (LON:HIK) Given Hold Rating at Berenberg Bank

Berenberg Bank reissued their hold rating on shares of Hikma Pharmaceuticals (LON:HIKFree Report) in a research report report published on Thursday morning, Marketbeat Ratings reports. Berenberg Bank currently has a GBX 2,000 ($24.70) target price on the stock.

Separately, Barclays restated an equal weight rating and set a GBX 2,000 ($24.70) target price on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of GBX 2,068.75 ($25.55).

View Our Latest Report on Hikma Pharmaceuticals

Hikma Pharmaceuticals Stock Up 3.2 %

Shares of LON:HIK opened at GBX 1,913 ($23.63) on Thursday. The stock has a market capitalization of £4.24 billion, a price-to-earnings ratio of 2,855.22, a PEG ratio of 2.38 and a beta of 0.45. Hikma Pharmaceuticals has a 12-month low of GBX 1,711 ($21.13) and a 12-month high of GBX 2,222 ($27.45). The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. The stock has a fifty day simple moving average of GBX 1,887.50 and a two-hundred day simple moving average of GBX 1,867.27.

Hikma Pharmaceuticals Increases Dividend

The firm also recently declared a dividend, which will be paid on Friday, May 3rd. Investors of record on Thursday, March 21st will be issued a $0.47 dividend. The ex-dividend date is Thursday, March 21st. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. Hikma Pharmaceuticals’s payout ratio is currently 8,507.46%.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

Read More

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.